Active clinical trials for "Conjunctivitis, Allergic"

To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after up to 14 days of at home dosing.

Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.

This study will evaluate the safety and efficacy of a new allergy medication

This post-marketing surveillance study will assess the safety and efficacy of Lastacaft® Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea.

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who are treated with Relestat as standard of care in clinical practice.

To evaluate the effect of Conjunctival Allergen Challenge (CAC) with Dust Mites on nasal and ocular allergic symptoms following allergen exposure in the Allergen BioCube (ABC).

To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.

The purpose of this study is to descriptively evaluate the corneal structures of allergic conjunctivitis patients.

An objective of this study is to standardize temperature values derived from thermograms of the facial region. It is anticipated that the mean temperature of a defined region of interest, such as the eyes, nose, or sinuses, might be useful for future applications. The investigators will attempt to determine normal temperature ranges based on participants' age and gender.